Brown Advisory
ACAD icon

Brown Advisory’s Acadia Pharmaceuticals ACAD Stock Holding History

Brown Advisory’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-6,025
Closed -$207K – 1214
2017
Q1 		$207K Buy
+6,025
New +$213K ﹤0.01% 1101
2016
Q1 		– Sell
-5,678
Closed -$203K – 994
2015
Q4 		$203K Buy
+5,678
New +$200K ﹤0.01% 902

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Brown Advisory's ACAD Position: Q2 2017 in Review

Brown Advisory sold out of Acadia Pharmaceuticals (ACAD) in Q2 2017, closing a stake of 6,025 shares — an estimated $207K sold.

Brown Advisory first reported a position in ACAD in Q4 2015 and held it in 2 quarters. The position peaked at $207K in Q1 2017. 203 funds tracked by Wall St. Rank hold ACAD as of Q2 2017.

  • Brown Advisory reported no remaining Acadia Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Brown Advisory sold 6,025 Acadia Pharmaceuticals shares in Q2 2017, an estimated $207K.
  • Brown Advisory first reported a position in Acadia Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • Brown Advisory's Acadia Pharmaceuticals position peaked at $207K in Q1 2017.
  • 203 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2017.

Based on Brown Advisory's 13F filing for Q2 2017, filed 14 Aug 2017.